QBI Coronavirus Research Group

QBI and Director Krogan’s COVID and infectious disease efforts continue to make waves

Thu Sep 21, 2023

Research!America President and CEO Mary Woolley (left) with QBI Director Nevan Krogan, PhD (center), and Pfizer Senior Vice President and Head of Vaccine Research and Development Annaliesa Anderson, PhD (right).

QBI publishes breakthrough on COVID-19 variants; Nevan Krogan recognized as trailblazer.

UCSF Quantitative Biosciences Institute and Institut Pasteur form center to fight infectious disease

Fri Oct 28, 2022

QBI Director Nevan Krogan, PhD, and Professor Stewart Cole, PhD, president of the Institut Pasteur, sign the memorandum of understanding for the new Institut Pasteur-UCSF QBI Center of Excellence in Emerging Infectious Diseases at a ceremony in the historic Musée Pasteur in Paris, France.

QBI Director Krogan receives the Legion of Honor, France’s highest award

Beyond the spike protein

Mon Jan 3, 2022

NIAID/NIH

A human cell (green) infected with SARS-CoV-2 virus particles (purple). Research from QBI has identified how the Alpha variant of the virus evades the human immune system.

Findings from QBI point to a host of viral proteins that enable SARS-CoV-2 variants to evade the immune system.

Cancer drug stops SARS-CoV-2 in the lab

Thu Feb 11, 2021

PharmaMar

Aplidin is extracted from Aplidium albicans, a sea squirt found off the coast of Spain.

“If you get a drug that targets a human protein, it would be incredibly hard for the virus to mutate away from being reliant on it,” said Nevan Krogan, the director of QBI.

QBI probes three lethal coronaviruses to find possible drug targets

Fri Oct 23, 2020

Blue dots show MERS-CoV particles on the surface of a cell

National Institute of Allergy and Infectious Diseases (NIAID)

Middle East respiratory syndrome coronavirus (MERS-CoV) viral particles under an electron microscopic.

“This is looking across coronaviruses and finding the commonalities so we’re in a better position to attack SARS3 when it comes,” said Nevan Krogan, the director of QBI.

Danica Fujimori Receives Bowes Biomedical Investigator Award

Fri Sep 18, 2020

Danica Galonić Fujimori, PhD

Danica Galonić Fujimori, PhD, will receive $1.25 million in funding over the next five years from the endowment of the late William K. Bowes, Jr., a venture capitalist and longtime UCSF supporter.

Nanobody-based antiviral developed at UCSF effectively blocks SARS-CoV-2 in the lab

Wed Aug 12, 2020

Noah Berger

The antiviral invented by Aashish Manglik, PhD, and colleagues is effective at blocking SARS-CoV-2 infection even as an aerosolized spray, according to laboratory testing.

School scientists developed an antiviral that fights SARS-CoV-2 that can be given as a nasal spray.

How targeting a key SARS-CoV-2 enzyme could lead to an antiviral drug

Fri Jul 10, 2020

Elisabeth Fall

James Fraser, PhD

The chemical fragments could bind to and disable an enzyme that helps the virus replicate.

SARS-CoV-2 may spur growth of molecular “railways” out of infected cells, School scientists show

Thu Jul 2, 2020

NIAID/NIH

SARS-CoV-2 viral particles and human cells

UCSF-led collaboration uncovers new avenues for COVID-19 drug discovery

COVID-19 relies on cell’s ‘master regulators’ for survival

Tue Jun 30, 2020

Topics and Expertise: QBI Coronavirus Research Group